Charlie Kimball is returning to AJ Foyt Racing for another run at the Indianapolis 500. (IndyCar Photo)
Charlie Kimball is returning to AJ Foyt Racing for another run at the Indianapolis 500. (IndyCar Photo)

Kimball Back With Foyt For Another Indy 500 Attempt

MOORESVILLE, N.C. – Charlie Kimball will make another attempt at the Indianapolis 500 as the NTT IndyCar Series race winning driver returns to A.J. Foyt’s team in May.

Kimball, who drove to victory in the 2013 Honda Indy 200 at Mid-Ohio for Chip Ganassi Racing, will compete in two races for A.J. Foyt Racing. He will also compete in the GMR Grand Prix on the Indianapolis Motor Speedway road course on May 15 and the 104th Indianapolis 500 on May 30.

Kimball will drive the No. 11 Tresiba Chevrolet and will partner with longtime sponsor, Novo Nordisk, for the 13th consecutive season.

“I am excited to once again represent Novo Nordisk and the diabetes community and to join A.J. Foyt Racing for the month of May,” Kimball said. “I have never run at Indianapolis without Novo Nordisk and to be able to return this year with the support of the legendary A.J. Foyt, Larry Foyt, and everyone at A.J. Foyt Racing, will certainly be special.”

For the month of May, Kimball will be part of a three-car effort from the Texas-based team, partnering with Sebastien Bourdais in the No. 14 Chevrolet and Dalton Kellett in the No. 4 Chevrolet. Kimball ran the full 2020 season with Foyt and closed it out by finishing eighth in St. Petersburg, Fla.

“It’s awesome to have Charlie and Novo Nordisk back for the month of May,” said Larry Foyt, president of A.J. Foyt Racing. “They were both great to work with throughout the challenges of 2020, and I’m glad we can continue the program. Charlie is focused on producing great results, and we are working hard to put the best group together for success.”

In 155 races, Kimball has posted six podium finishes, and an additional eight top-fives. He has finished in the top-10 45 times and has led 163 laps.

“Over the last 13 years, Charlie Kimball and Race with Insulin have become an important part of Novo Nordisk,” said Chip Amrein, lifecycle management and connected care lead. “We are pleased to join A.J. Foyt Racing for both the Indianapolis Grand Prix and the Indianapolis 500 this year and to continue supporting Charlie as an ambassador and inspiration within the diabetes community.”